ABOS — Acumen Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $65.42m
- -$76.72m
- 17
- 51
- 20
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.36 | ||
| Price to Tang. Book | 0.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.94% | ||
| Return on Equity | -45.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.44 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
Directors
- Daniel O'Connell PRE (51)
- Grant Krafft CFD
- W. Matthew Zuga CFO (56)
- Russell Barton COO (63)
- Eric Siemers OTH (66)
- Nathan Fountain IND (58)
- Jeffrey Ives IND (70)
- Jeffrey Sevigny IND (52)
- Sean Stalfort IND (51)
- Laura Stoppel IND (35)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 4th, 1996
- Public Since
- July 1st, 2021
- No. of Shareholders
- 67
- No. of Employees
- 61
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 60,573,425
- Address
- 427 PARK ST., CHARLOTTESVILLE, 22902
- Web
- https://acumenpharm.com/
- Phone
- +1 9253688508
- Auditors
- Ernst & Young LLP
Upcoming Events for ABOS
Acumen Pharmaceuticals Inc Annual Shareholders Meeting
Acumen Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Acumen Pharmaceuticals Inc Earnings Release
Similar to ABOS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Acumen Pharmaceuticals share price?
As of Today at 24:18 UTC, shares in Acumen Pharmaceuticals are trading at $1.08. This share price information is delayed by 15 minutes.
How has the Acumen Pharmaceuticals share price performed this year?
Shares in Acumen Pharmaceuticals last closed at $1.08 and the price had moved by -68.97% over the past 365 days. In terms of relative price strength the Acumen Pharmaceuticals share price has underperformed the S&P500 Index by -72.02% over the past year.
What are the analyst and broker recommendations for Acumen Pharmaceuticals?
The overall consensus recommendation for Acumen Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Acumen Pharmaceuticals dividend yield?
Acumen Pharmaceuticals does not currently pay a dividend.
Does Acumen Pharmaceuticals pay a dividend?
Acumen Pharmaceuticals does not currently pay a dividend.
When does Acumen Pharmaceuticals next pay dividends?
Acumen Pharmaceuticals does not currently pay a dividend.
How do I buy Acumen Pharmaceuticals shares?
To buy shares in Acumen Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acumen Pharmaceuticals?
As of the previous close price of $1.08, shares in Acumen Pharmaceuticals had a market capitalisation of $65.42m.
Where are Acumen Pharmaceuticals shares listed?
Here are the trading details for Acumen Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ABOS
What kind of share is Acumen Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Acumen Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acumen Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Acumen Pharmaceuticals is $9.20. That is 751.85% above the last closing price of $1.08.
Analysts covering Acumen Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.26 for the next financial year.
Find out moreWhat is the trend in the Acumen Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acumen Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -61.86%.
As of the last closing price of $1.08, shares in Acumen Pharmaceuticals were trading -47.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acumen Pharmaceuticals PE Ratio?
The Acumen Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acumen Pharmaceuticals?
Acumen Pharmaceuticals' management team is headed by:
- Daniel O'Connell - PRE
- Grant Krafft - CFD
- W. Matthew Zuga - CFO
- Russell Barton - COO
- Eric Siemers - OTH
- Nathan Fountain - IND
- Jeffrey Ives - IND
- Jeffrey Sevigny - IND
- Sean Stalfort - IND
- Laura Stoppel - IND